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Background: MP-AzeFlu (Dymista; spray of azelastine/fluticasone propionate) is the most
effective allergic rhinitis (AR) treatment available. Its effect on asthma outcomes in patients with AR
and asthma is unknown.
Methods: This pre-post historical cohort study, using the Optimum Patient Care Research
Database, included patients aged 12 years, from UK general practice with active asthma (defined
as a recorded diagnosis, with 1 prescription for reliever or controller inhaler) in the year before or
at the initiation date. The primary study outcome was change in number of acute respiratory events
(i.e. exacerbation or antibiotic course for a respiratory event) between baseline and outcome
years. The effect size of MP-AzeFlu was quantified as the difference in % of patients that improved
and worsened.
Results: Of the 1,188 patients with AR and asthma included, many had a record of irreversible
obstruction (67%), and uncontrolled asthma (70.4%), despite high mean daily doses of reliever/
controller therapy and acute oral corticosteroid use, in the year pre-MP-AzeFlu initiation. MP-
AzeFlu initiation was associated with fewer acute respiratory events (effect size (e) ¼ 5.8%,
p ¼ 0.0129) and a reduction in daily use of short-acting b2-agonists, with fewer patients requiring
>2 SABA puffs/week (e ¼ 7.7% p < 0.0001). More patients had well-controlled asthma 1-year
post-MP-AzeFlu initiation (e ¼ 4.1%; p ¼ 0.0037), despite a reduction in inhaled corticosteroids
(e ¼ 4.8%; p ¼ 0.0078).
Conclusions: This study provides the first direct evidence of the beneficial effect of MP-AzeFlu on
asthma outcomes in co-morbid patients in primary care in the United Kingdom.
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Allergic diseases are complex and can cluster in
multi-morbidities.1 One such example is the
concurrence of allergic asthma and rhinitis in the
same patient.2–4 These diseases are linked on
several levels, often referred to as the “one
airway one disease” or “unified airway disease”
concept.5,6 Evidence to support this link comes
from epidemiological, pathophysiological,
clinical, and socioeconomic studies.2,3 For
example, the prevalence of asthma is more than
6 times higher in those with rhinitis than in those
without.7 Both diseases share contiguous
anatomy, triggers, and inflammatory
processes.2,3,8 Control of these diseases is also
linked, with control of one affecting control of the
other.9 Furthermore, co¼morbid patients
experience more asthma exacerbations,10,11 use
more asthma medication,12 and have more
physician and hospital visits for their asthma.13,14
Taking this into account, reducing inflammation
in the nose should improve outcomes in the lungs
for those patients with both diseases, a theory
endorsed by allergic rhinitis (AR) management
guidelines.8,15 Treating both asthma and AR
together results in better asthma outcomes,
including an improvement in lung function, and a
reduction in asthma-related hospitalizations and
exacerbations.16–18 The “AR treatment efficacy
hierarchy concept” takes this one step further,
postulating that more effective AR control should,
in turn, have a greater positive impact on multi-
morbid asthma control. Part of this hierarchy hasFig. 1 Pre-post, historical, cohort study design.already been proven: intranasal corticosteroids
(INS) provide better AR symptom control than oral
anti-histamines (OAHs),19 and as a consequence,
unlike OAHs, INS have a positive impact on many
asthma outcomes, including lung function and
reduced asthma rescue medication use.20,21
However, many AR patients remain symptomatic
on INS monotherapy (and multiple therapies),22
perhaps due to a recently identified INS efficacy
ceiling.23 Could a more effective AR treatment
confer greater synergistic benefits for asthma
outcomes in co-morbid patients?
MP-AzeFlu comprises an INS (fluticasone pro-
pionate; FP) and an intranasal anti-histamine (aze-
lastine; AZE) in a patented formulation, delivered
in a single spray. In the United Kingdom, MP-
AzeFlu has been available since 2013 on pre-
scription only, and it is fully reimbursed, subject to
a standardised co-pay that applies to all UK pre-
scriptions. It is indicated for the treatment of both
seasonal and perennial AR.24 It is currently the
most effective symptomatic pharmacotherapy for
the treatment of AR (twice as effective as an INS),
with the fastest onset of action (5 min).23,25–27
Although, socioeconomic evidence for MP-
AzeFlu’s positive effect on asthma control in AR
and asthma co¼morbid patients has previously
been published,28 a direct effect on asthma
control is missing. An assessment of the effect of
AR treatment on asthma outcomes in real-life is
also warranted; previous evidence with INS has
come from randomized controlled trials (RCTs),
21
the results of which may not be generalizable to
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routine clinical care.29–31 The aim of the current
study was to investigate the real-life effect of MP-
AzeFlu on asthma outcomes in patients with both
AR and asthma in UK primary care.METHODS
Study design
This was a 2-year, pre-post, historical cohort
study, using data from the Optimum Patient Care
Research Database (OPCRD),32 to compare
asthma-related outcomes in the period before
and after initiation of MP-AzeFlu (ie, index pre-
scription date; Fig. 1). This self-controlled study
design ensured that patient characteristics which
were stable over the study period could not affect
the associations of interest. The index prescription
date (IPD) was the date at which patients received
their first prescription of MP-AzeFlu. The OPCRD
dataset contains patient records from June 1930 to
March 2019; MP-AzeFlu first became available in
the United Kingdom in 2013. Baseline data were
captured at least a minimum of one year prior to
MP-AzeFlu prescription, and outcome data (ie,. toFig. 2 Subject disposition. Patients within the Optimum Patient Care D
corticosteroidsassess the impact of MP-AzeFlu on asthma-related
outcomes) were captured in the year after MP-
AzeFlu prescription. The study protocol was
approved by the Anonymized Data Ethics and
Protocols Transparency (ADEPT) committee.
ADEPT is an independent body of experts and
regulators commissioned by the Respiratory
Effectiveness Group to govern the standard of
research conducted on internationally recognised
databases.33 The study protocol was registered
with the European Union electronic Register of
Post-Authorization studies.34
Data source
The OPCRD comprises medical records of more
than 7 million patients from over 700 general
practices across the United Kingdom (approxi-
mately 8% of the total UK population) and in-
tegrates with all UK clinical systems (EMIS, TPP
SystmOne, InPS Vision, Microtest Evolution). It
benefits from a long retrospective period (median
time in the database is 13 years, goes back to birth
for summary diagnostic data in many cases), and
contains linked patient-completed respiratory
questionnaires for approximately 10% of asthmaatabase who fulfilled study inclusion criteria. OCS: oral
Term Definition
Acute respiratory event 1 of any of: (i) asthma-related primary care-
recorded hospital admissiona, (ii) asthma-related
primary care-recorded A&E attendanceb, (iii) acute
course of OCS, (iv) antibiotics course with evidence
of respiratory consultation. Occurrences within 14
days of each other were considered to belong to
the same event.
Asthma exacerbation 1 of any of: (i) asthma-related primary care-
recorded hospital admission, (ii) asthma-related
primary care-recorded A&E attendance, (iii) acute
course of OCS. Occurrences within 14 days of each
other were considered to belong to the same event.
GINA treatment step37 Highest step during the baseline and outcome
years, with the daily dosage of ICS based on the last
prescription in each period.
RDAC38 The absence of an acute respiratory event (see
above) AND an asthma-related out-patient
department (specialist) consultation in the baseline
year.
OAC38 The absence of an acute respiratory event (see
above) AND an asthma-related out-patient
department (specialist) consultation AND an
average daily dose of SABA >200 mg salbutamol/
>500 mg terbutaline in the baseline year.
GINA control status37 Based on a yes/no response to GINA control
question:
 Day times symptoms >2/week
 Any night wakening due to asthma
 Reliever medication >2/week
 Any activity limitation due to asthma
0 ‘yes’ ¼ well controlled; 1–2 ‘yes’ ¼ partly
controlled; 3–4 ‘yes’ ¼ uncontrolled
Average daily dose of SABA >2 puffs of SABA per
week
Based on collected prescriptions in the baseline
year. Calculated as count of inhalers  doses in
pack  mg strength/365. Expressed as salbutamol
equivalent in mg/day.
>28,571 (more than 2 puffs a week) mg/day.
Average daily dose of ICS Based on collected prescriptions in the baseline
year. Calculated as count of inhalers  doses in
pack  mg strength/365). Expressed as fluticasone
propionate equivalent in mg/day.
Adherence Calculated by the medication possession ratio.
Refill rate (%) ¼ (total ICS pack days/number of
prescription days)*100
Table 1. Summary of asthma outcome definitions. A&E: Accident & Emergency; OCS: oral corticosteroids; ICS inhaled corticosteroid; RDAC: Risk
Domain Asthma Control; OAC: overall asthma control; SABA: short-acting b2-agonist. a. Definite asthma hospital admission OR a generic hospitalization. Read
code which has been recorded on the same day as a lower respiratory consultation. b. Definite asthma on emergency attendance OR a generic emergency.
Hospital Read code which has been recorded on the same day as a lower respiratory consultation
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measures within the OPCRD have been validated
using patient reported outcomes.35
Patients
Patients included in this analysis had received at
least 1 prescription for MP-AzeFlu, were aged  12
years old (at IPD) and had “active” asthma (Fig. 2).
As MP-AzeFlu is indicated solely for AR (both
seasonal and perennial) in the United Kingdom, it
was assumed that all patients included in the study
had AR. Analysis of upper respiratory disease
diagnostic codes ever, prior to MP-AzeFlu initiation
showed marked coding overlap, reflecting patient
journeys to and within medical care services in the
United Kingdom and co-morbidity burdens ( S-
Fig. 1). Active asthma was defined as ever having
a recorded diagnostic Read code for asthma
before starting MP-AzeFlu, and 1 asthma ther-
apy prescription (ie, reliever and/or controller
medication) in the year prior to MP-AzeFlu initia-
tion. Eligible patients were required to have at
least 2 years of data, comprising 1 year of data
before (baseline year) and after MP-AzeFlu initia-
tion (outcome year). Patients with only a diagnosis
of chronic obstructive pulmonary disease ever
before or a prescription for maintenance oral cor-
ticosteroids (OCS) and biologics in the year prior
to MP-AzeFlu prescription were excluded (Fig. 2).
Study outcomes
The primary outcome was change (from base-
line year to outcome year) in the number of acute
respiratory events. An acute respiratory event was
defined when 1 or more of the following applied:
an asthma-related primary care-recorded hospital
admission; an asthma-related primary-care recor-
ded accident and emergency(A&E) attendance; an
acute course of OCS; an antibiotic course with
evidence of respiratory consultation. This definition
has previously been validated as part of the Risk
Domain Asthma Control questionnaire.35 An
occurrence of any of these factors within 14 days
of each other was considered to belong to the
same event (Table 1). The secondary outcome
was change in the number of asthma
exacerbations. An exacerbation was defined
according to American Thoracic Society/
European Respiratory Society (ATS/ERS). Task
Force definition (Table 1).36 Exploratoryoutcomes included change in: (i) asthma Global
Initiative for Asthma (GINA) 201837 treatment
step; (ii) asthma control; (iii) average daily dose
of short-acting b2-agonist (SABA) or >2 puffs of
SABA per week; and (iv) average daily dose of
inhaled corticosteroids (ICS). Asthma control was
assessed in 3 ways; risk domain asthma control
(RDAC), overall asthma control (OAC) and GINA
control status (ie, controlled, partly-controlled, and
un-controlled).35,37,38 A definition of each of these
outcomes is provided in Table 1 and in the online
supplement under the section entitled "Study
outcomes: definitions".Statistical analysis
The Wilcoxon’s signed rank test for paired data
calculated that 1103 patients were required to
detect a difference in the primary outcome vari-
able (ie, number of acute respiratory events) be-
tween the outcome and baseline years, with an
effect size of 0.1 and 90% statistical power at a
significance level of 0.05. All outcome variables
were defined a priori. Baseline variables with
missing data were presented as the number of
non-missing observations.
Summary statistics were used to describe the
distribution of demographic and clinical charac-
teristics in the year prior to IPD. The number of
acute respiratory events, number of exacerbations,
GINA treatment step, GINA control status, and
average daily dose of SABA or ICS in the baseline
and outcome years were compared using the
Wilcoxon signed rank test (for paired data).
Change in asthma control (assessed by RDAC and
OAC) was assessed using the McNemar’s test. A p-
value of 0.05 was considered statistically signifi-
cant. Each of these asthma outcomes was reported
as the proportion of patients who improved,
worsened and remained stable in the outcome
year. The effect of the intervention was expressed
as the difference in the percentage of patients
improving and worsening on a certain asthma
outcome.
These analyses were performed in the total
population and for those: (i) with and without a
prescription of INS in the past 45 days (ie, active vs
not active INS use), (ii) ever or never treated with
INS, (iii) who had 0 or 2 exacerbations in the year
prior to the index date, and (iv) in those with blood
Fig. 3 Co-morbidities experienced by patients with AR and active asthma (12 years old) attending primary care in the UK, in the year prior
to MP-AzeFlu initiation (n ¼ 1188).CRS: chronic rhinosinusitis; HT: hypertension; GERD: gastroesophageal reflex disease; NP: nasal polyps;
CVD: cardiovascular disease; DM: diabetes mellitus; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease (*stage 3–
5); ISH: Ischaemic heart disease; OSA: obstructive sleep apnoea; MI: myocardial infarction; HF: heart failure
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the 5 years prior to and up to MP-AzeFlu initiation,
to assess whether these had an impact on asthma
control variables assessed. In this self-controlled
study design ICS may be a potential confounder
(ie, the initiation of MP-AzeFlu may be associated
with a change in ICS, and ICS may be associated
with a change in asthma-related outcomes) and an
analysis adjusting for ICS was also conducted (S-
Table 2). In case of controlling for confounders, a
conditional logistic regression was used for
binary outcomes. Findings were reported as
odds ratio (OR) and 95% CI. For count outcomes,
a conditional negative binomial regression was
used when we adjusted for confounders. The
results were reported as rate ratio and
corresponding 95% confidence interval (CI). For
outcomes with more than two categories (eg,
GINA step), adjustment for confounders
conditional multinomial logistic regression was
used. For this analysis the odds ratio (OR) and
95% CI were presented. All statistical analyses
were performed using Stata MP6 V.15 and Stata
SE V.14 (StataCorp, College Station, Texas, USA).RESULTS
Study population
From an initial 11323 patients in the OPCRD
who received MP-AzeFlu treatment, 1188 patients
met all inclusion criteria and were included in the
analysis (Fig. 2).Baseline characteristics (year prior to MP-AzeFlu
prescription)
Demographic
Patients who were prescribed MP-AzeFlu were
most likely to be aged between 18 and 64 years
old, female, over-weight/obese, with a smoking
history (past or present; Table 2). The average
(standard deviation) number of MP-AzeFlu pre-
scriptions in the outcome year was 1.54 (2.74).Baseline co-morbidities and rhinitis treatments
Multi-morbidity was evident. The top 3 most
common co-morbidities recorded (in addition to
AR and asthma) were depression/anxiety (n ¼ 479;
40.3%), eczema (ever: n ¼ 370 [31.1%]; active:
n ¼ 71 [6.0%]), and chronic rhinosinusitis (CRS;
n ¼ 314; 26.4%; Fig. 3). Other less commonly
recorded co-morbidities (but still >10%) included
hypertension, gastroesophageal reflux disease
(GERD; ever), and nasal polyps (NP; Fig. 3).
Indeed, 63 patients (5.3%) suffered from both
CRS and NP (CRSwNP) (in addition to AR and
asthma). The most common AR treatments used
prior to MP-AzeFlu prescription were INS and
OAHs (Fig. 4A). Over a quarter of patients
(n ¼ 319; 26.9%) were prescribed eye drops, and
of those patients, most used chromones
(n ¼ 111/319; 34.8%). A non-steroidal nasal spray
was used by 14.1% of patients (n ¼ 167), with sa-
line nasal spray being the most common in this
subset (n ¼ 84/167; 50.3%) (Fig. 4A). Rhinitis poly-
Fig. 4 (A) allergic rhinitis (AR) treatments and (B) asthma treatments prescribed to patients with AR and active asthma (12 years old)
attending primary care in the UK, in the year prior to MP-AzeFlu initiation (n ¼ 1188). (A) INS: intranasal corticosteroids; OAH: oral anti-
histamine; ED: eye drops (*including chromones, anti-histamines, corticosteroids, ocular lubricants, antibiotics and astringents); non-
steroidal NS: nasal spray (†including anti-histamines, anti-cholinergics, chromones, leukotriene receptor antagonists [with diagnosis of
rhinitis on the same day]), decongestants and saline).(B) SABA: short-acting b2-agonist; ICS: inhaled corticosteroid; LABA: long-acting b2-
agonist; LTRA: leukotriene receptor antagonist; SAMA: short-acting muscarinic antagonist; NaCrGly: sodium cromoglycate
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(n ¼ 612; 51.5%) were prescribed 2 rhinitis
treatments in the year prior to MP-AzeFlu initiation
(Fig. 4A).Baseline asthma clinical characteristics and
treatment
Patients in this study had asthma of relatively
late onset (although the standard deviation [SD]
was large) and of long duration (Table 2). Although
the % predicted peak expiratory flow (PEF) and
forced expiratory volume in 1 s (FEV1) were77.3% and 85.1%, respectively, at baseline, many
patients did show evidence of obstruction; over
1/3 of them (36.6%; n ¼ 56/153) had a %
predicted FEV1 <80% (S-Table 1) and 29.0%
(n ¼ 67/231) had a post-bronchodilator FEV1/
forced vital capacity (FVC) < 0.7. Severe asthma
was noted in 13.1% (n ¼ 156) of patients (defined
as those on GINA Step 5 treatment or with un-
controlled asthma on GINA Step 4) and over a
quarter of patients had 2 asthma consultations
(excluding annual review visit) in the year prior to
MP-AzeFlu prescription (Table 2). Furthermore,
Variable Variable
Age, years, Mean (SD) 46.8
(19.0)
Age of asthma onseta, yrs, Mean (SD)
(n [ 619)
24.5 (18.4)
12-17, n (%) 113 (9.5) Duration of asthmab, yrs, Mean (SD)
(n [ 619)
22.6 (12.8)
18-64, n (%) 830
(69.9)
BECc, Mean (SD) (n [ 921) 0.3 (0.4)
65, n (%) 245
(20.6)
<0.25, n (%) 433 (47.0)
0.25, n (%) 488 (53.0)
Sex PEFd, % predicted, Mean (SD) (n [ 401) 77.3 (19.7)
Women, n (%) 694
(58.4)
FEV1
e, % predicted, Mean (SD) (n [ 153) 85.1 (22.6)
Smoking status, ever
(n [ 1163)
FEV1,  80% predicted, n (%) (n [ 153) 97.0 (63.4)
Never, n (%) 475
(40.8)
FEV1/FVC
e, Mean (SD) (n [ 231) 0.8 (0.1)
Current, n (%) 150
(12.9)
FEV1/FVC
e < 0.7, n (%) 67.0 (29.0)
Former, n (%) 530
(46.3)
BMI, kg/m2 (n [ 1038), Mean
(SD)
27.6 (6.3) Severe asthmaf, n (%) 156 (13.1)
Underweight: <18.5, n (%) 50 (4.8) Daily dose, mg/day mean (SD)








Obese: 30, n (%) 307
(29.6)




Table 2. Baseline characteristics of patients with allergic rhinitis and asthma before initiation of MP-AzeFlu (n ¼ 1188). SD: standard deviation;
BMI: body mass index; BEC: blood eosinophil count; PEF: peak expiratory flow; FEV1: forced expiratory flow in 1 s; FVC: forced vital capacity; ICS: inhaled
corticosteroid; SABA: short-acting b2-agonist. a. Age of asthma onset was determined as when patients had their first diagnostic code for asthma either:1 year
after the date of joining the general practice, and when they did not receive a prescription of asthma medication in that year OR. Before the date when they
joined the general practice and when they did not receive a prescription of asthma medication before they joined the practice. b. Time between the date of MP-
AzeFlu initiation and the date of the first diagnostic code for asthma in years. c. No steroid use 2 weeks prior to measurement (109/L); d. Last recorded values
closest to index date prior to 5 years (>18 yrs old) or last recorded value closest to index date prior to 2 years (15–18 yrs old); e. Last recorded value closes to
IPD prior to 5 years. f. Receiving GINA treatment step 4 plus  2 exacerbations in baseline year or receiving GINA Step 5 treatment in the baseline year;
g. Based on collected prescriptions in the baseline year, salbutamol or fluticasone propionate equivalent. h. An asthma-related consultation but not for annual
monitoring/review
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respiratory event, and 37.7% (n ¼ 448) had 1
asthma exacerbation. Only 9.6% (n ¼ 58/604) of
patients had controlled asthma (GINA definition)
in the baseline year (Table 3).In terms of asthma treatment, 53.5% (n ¼ 635) of
patients were on GINA step 4 in the baseline year
(Table 3); the most common prescriptions were
SABA, ICS/long-acting b2-agonist (LABA), ICS,
and leukotriene receptor antagonist (LTRA)

































3, n (%) 76 (6.4) 48 (4.0)
4, n (%) 71 (6.0) 82 (6.9)
Secondary outcome
Asthma exacerbations based on
ATS/ERS Force definition, number














2, n (%) 100 (8.4) 107 (9.0) Worsened:
226
(19.0%)
3, n (%) 42 (3.5) 28 (2.4)
4, n (%) 58 (4.9) 69 (5.8)
Exploratory outcomes
























5, n (%) 0 (0.0) <5c



































































17 (2.8) 18 (3.0)
Average daily dose of SABA
based on collected prescriptions,
salbutamol equivalent in mg/day

























































































Table 3. (Continued) Asthma-related outcomes in the period before and after initiation of the combination therapy azelastine
hydrochloride/fluticasone propionate among patients with allergic rhinitis and asthma multi-morbidity (n ¼ 1188). Abbreviations: MP-AzeFlu,
azelastine hydrochloride/fluticasone propionate; ATS/ERS: American Thoracic Society/European Respiratory Society; SABA, short-acting beta agonist; ICS,
inhaled corticosteroids; FP, fluticasone propionate; SMD, standardised mean difference.Controlled ¼ none of the questions have a “yes” response; Partly
controlled ¼ 1–2 of the questions have a “yes” response; Uncontrolled ¼ 3–4 of the questions have a “yes” response. a. The effect of the intervention was
expressed as the difference in the percentage of patients improving and worsening on a certain asthma outcome b. P-value for the Wilcoxon signed-ranks test
(categorical variables), or the McNemar’s test (dichotomous variables), where appropriate. c. Data suppressed to comply with privacy requirements (less than a
count of 5 in a cell). d. Risk Domain asthma control (RDAC) (yes/no), defined as absence of any of the following events in the baseline year. 1. Acute respiratory
event (primary outcome as defined above), and. 2. Asthma-related outpatient department (specialist) consultation. e. Overall asthma control (OAC) (yes/no),
defined as absence of any of the following events in the baseline year: 1. Acute respiratory event (primary outcome), and 2. Asthma-related outpatient
department (specialist) consultation, and 3. Average daily dose of SABA >200 mg salbutamol/>500 mg terbutaline. f. GINA control status: poor asthma
symptom control is defined as 3 out of 4 of the following: 1) “yes” to 3 RCP questions. 2) >2 puffs of SABA per week
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antagonist [LAMA]: 7.7%, n ¼ 92; and LTRA: 22.7%,
n ¼ 270). The average daily dose of ICS (FP
equivalent in mg/day) was high (303.9 mg [SD
386.6]), with 40.7% of patients (n ¼ 484) pre-
scribed a dose of >250 mg/day. Mean daily SABA
dose was also high (325 mg [SD 387.8]), as was
acute OCS use, with 35.8% (n ¼ 425) of patients
having at least 1 acute OCS prescription in the
baseline year (Fig. 4B). Despite this relatively high
steroid burden (both inhaled and oral), blood
eosinophil count (BEC) was 0.25 cells/ml (x
109 cells) for 53% (n ¼ 488/921) of patients
(Table 2). Macrolides were prescribed (at least
once) to 22.6% (n ¼ 268) of patients during the
baseline year (Fig. 4B). A total of 43 patients
(3.6%) had 3 prescriptions of macrolides in the
year prior to MP-AzeFlu prescription.Asthma outcomes (year after MP-AzeFlu
prescription)
Main analysis
Patients with AR had a significant reduction of
acute respiratory events during the study period
(p ¼ 0.0129), with an effect size of 5.8% more pa-
tients improving than worsening. Patients with AR
and asthma had better asthma control assessed by
RDAC (effect size ¼ 4.4%; p ¼ 0.0045), OAC (effect
size ¼ 4.1%; p ¼ 0.0037) and by GINA control
status in the year after MP-AzeFlu prescription
compared with the year prior to prescription,
although the latter association did not reach sta-
tistical significance (effect size ¼ 1.6%; p ¼ 0.3532)
(Table 3). Although the number of asthma
exacerbations did not significantly reduce in the
year after MP-AzeFlu initiation, there were 2.4%
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were with more. All of these improvements
occurred in an environment of stable or reduced
GINA treatment step (for 91.4% of patients), SABA
daily dose (11.2% more patients reduced their
dose than increased), and ICS daily dose (stable or
increased in 84.4% of patients) (Table 3).
Supplementary analysis
Although findings were in a similar direction
when corrected for ICS, they were non-significant
(Online Supplement S-Table 2). Asthma outcomes
for those with and without a prescription of INS
in the 45 days prior to MP-AzeFlu initiation (On-
line Supplement S-Table 3A and 3B), or for those
who had ever or never been prescribed an INS
prior to IPD (Online Supplement S-Tables 4A &
4B) were almost consistent with the main
analysis. In patients with an INCS in the 45 days
prior to MP-AzeFlu initiation, opposite effects for
the number of exacerbations and OAC were
observed, but with less precision due to the small
sample size. For patients with 0 or 2 exacerbations
in the year prior to MP-AzeFlu initiation, almost all
asthma outcomes were consistent with the findings
of the main analysis, with the exception of number
of exacerbations. In this study population, there
were 1.4% more patients with more exacerbations
than there were with fewer exacerbations, but the
number of patients with 0 exacerbations in the
year prior to MP-AzeFlu initiation were higher in
this study population (68.0% pre-initiation of MP-
AzeFlu and 70.4% post-initiation) than in the
main analysis (Online Supplement S-Table 5).
Finally, the impact of MP-AzeFlu on asthma out-
comes was more apparent in those patients with a
BEC <0.25 109/L (vs  0.25 109/L; Online Sup-
plement S-Tables 6A & 6B). However, in the high
eosinophilic group MP-AzeFlu was still associated
with a significant reduction in SABA use (both in
terms of a reduction in average daily dose and
requirement for > 2 puffs/week) (Online Supple-
ment S-Table 6B).
DISCUSSION
This study is the first to show an association
between MP-AzeFlu use for AR and improvement
in multiple, clinically-relevant, and validated
asthma outcomes in real-life clinical practice. MP-
AzeFlu use was associated with fewer acuterespiratory events and better asthma control in
patients with AR and asthma, with a small number
of asthma exacerbations prior to MP-AzeFlu initi-
ation. Perhaps more importantly, these benefits
occurred despite stable/reduced ICS dose, and in
asthma characterized by high treatment (including
acute OCS use) and co¼morbidity burdens, and
was also associated with reduced SABA use. These
patients were also frequently treated with multiple
AR therapies prior to MP-AzeFlu initiation.
Furthermore, asthma benefits were noted in those
previously treated with INS (either recently, or
ever) and in those with a history of asthma exac-
erbations in the year prior to MP-AzeFlu initiation.
Although, asthma outcomes did not improve in all
patients, considering that AR and asthma are
among the most prevalent chronic diseases in the
world, carrying a high symptomatic and economic
burden,22,39–41 any indication of therapeutic
improvement is welcome.
The positive effect of INS in improving asthma
outcomes in asthma and AR co-morbid patients is
well-established.17,18,20,21 However, it is worth
noting that some studies failed to show an
effect.42–44 This may have been because asthma
was relatively mild or well-treated, leaving little
room for improvement.42,43 Additionally, these
studies were of relatively short duration (4–6
weeks), which likely provides insufficient time in
which to capture less frequent (or intermittent)
evidence of poorly controlled asthma (eg,.
exacerbations).42,43 Study size may also have
been a factor, leading to a lack of power to
detect an effect.44 These limitations did not
apply to our study. Patients included in the
current study had difficult/severe to manage
asthma, with plenty of room for improvement.
Many patients exhibited irreversible airway
obstruction, multiple exacerbations, and poor
control, despite evidence of ICS/LABA and acute
OCS prescriptions. The patients frequently
suffered from other co-morbid conditions in
addition to AR, such as CRS, NP, and eczema, and
tended to have late onset asthma. High
co¼morbidity burden and late onset are features
of severe asthma,45 and indeed 13.1% of patients
in our study had a confirmed diagnosis of severe
asthma. This is likely an under-estimation; a
recent analysis from the OPCRD showed that the
majority of patients with severe asthma in primary
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care for a confirmed diagnosis.46 These factors
may explain, in part, why MP-AzeFlu did not
significantly improve all asthma outcomes investi-
gated (eg, exacerbation rate and GINA control
status). However, it is worth noting that although
the study was not powered to detect a significant
difference in these exploratory outcomes, AR and
asthma patients treated with MP-AzeFlu did show a
significant improvement in asthma control when
assessed using both the RDAC and the OAC. Our
study was also of sufficient duration and size to
study the impact of MP-AzeFlu on asthma out-
comes. A total of 1188 AR and asthma co¼morbid
patients provided at least 1 full year of data prior
to, and after, MP-AzeFlu initiation (which also
minimized seasonal bias).
Two previously published socioeconomic
studies have provided indirect evidence of MP-
AzeFlu’s potential to improve asthma control (as a
consequence of effectively treating AR).28,47 The
first of these, a retrospective claims study for
commercially insured patients in the United
States, compared MP-AzeFlu with the free combi-
nation of intranasal FP plus intranasal azelastine,
on healthcare resource utilization and costs for
patients with AR and asthma.28 It found that
asthma-related costs were lower for MP-AzeFlu
users (versus those who used the loose combina-
tion). Lower asthma pharmacy costs (on MP-
AzeFlu), implies less asthma medication usage
(also found in our study), which is a surrogate
marker of improved asthma control. A second so-
cioeconomic study using Danish National Pre-
scription and Patient Registries data confirmed no
increase in asthma medication use for patients on
MP-AzeFlu to treat their AR.47 Conversely, a
significant increase in asthma medication use was
noted for patients using concurrent INS þ OAH
therapy.47
Stronger evidence has been forthcoming from a
2-week, prospective, non-interventional study
which evaluated the effectiveness of MP-AzeFlu in
controlling AR in different AR phenotypes
(including patients with AR þ asthma, and those
with multi-morbidities).48,49 Effectiveness was
assessed using a visual analogue scale (VAS). The
study showed that 76.5% and 72.8% of multi-
morbid and asthma co-morbid patients, respec-
tively, responded to MP-AzeFlu (where responsewas defined as 1 VAS score <50/100 mm), and
experienced a rapid, statistically significant, and
sustained improvement in AR control in the first
days of treatment.49 Improvement in AR control
was associated with a significant (p  0.002)
46.2% reduction in asthma VAS score from
baseline in patients with AR and asthma.
Furthermore, over two-thirds of these co-morbid
patients (69.2%) treated with MP-AzeFlu were
able to reduce, or considerably reduce, their
asthma rescue medication use.49 The findings
from our study show a similar MP-AzeFlu-
associated reduction in SABA use, but also an
improvement in many other clinically-relevant and
validated asthma outcomes, including asthma
control, reduction in GINA treatment step, number
of acute respiratory events and ICS dose.
What are the mechanisms underlying MP-Aze-
Flu’s beneficial effect on asthma outcomes? In or-
der for any nasally applied medication to have an
effect on the lower airways, it is necessary that the
nose and the lungs “talk” to each other (i.e. naso-
bronchial cross talk). This phenomenon has been
elegantly described by Braunstahl and col-
leagues.50 They found that nasal allergen
provocation induced an increase in adhesion
molecule expression (eg,. ICAM-1, VCAM-1) and
tissue eosinophilia in both the upper and lower
airway.50 With this channel of communication
“open”, an AR medication could exert an anti-
asthma effect by: reducing bronchial hyper-
responsiveness via re-establishment of primary
nasal functions (ie, air filtration and humidification);
via an interaction with the bronchial reflex mech-
anism; and by targeting inflammatory cells and
mediators common to both diseases (eg, the
eosinophil and its associated cytokines).2,3 MP-
AzeFlu has been shown to inhibit eosinophil sur-
vival and reduce IL-6 concentrations better than
either FP or AZE in a human nasal epithelial cell
model, an effect mediated via induction of anti-
inflammatory gene expression (ie, GILZ & MKP-
1).51,52 This MP-AzeFlu-induced anti-eosinophilic
effect was also apparent in the lower airways, evi-
denced by total abrogation of eosinophils in
bronchoalveolar lavage fluid from mice.53 Further
work is necessary to establish if nasally applied
AR medications have a systemic anti-
inflammatory effect. It is interesting to note; how-
ever, that surgical resection of NP coincides with a
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The results of our study have implications for the
management of asthma and AR co¼morbid pa-
tients and supports ARIA’s recommendation to
treat the respiratory tract (both upper and lower)
as a whole using a unified treatment approach.8
AR patients should be assessed for the presence
of asthma by history, and if needed confirmed by
reversibility to short-acting b2-agonist.
8
Conversely, patients with uncontrolled asthma,
should be assessed for the presence of AR,3
since asthma patients with significant rhinitis are
nearly 5 times more likely to have poorly
controlled asthma (compared to those without
rhinitis), with an odds ratio greater than that for
poor compliance with asthma therapy.9 A
combination of the most effective symptomatic
treatment for AR (ie, MP-AzeFlu), and appropriate
inhaled asthma therapy should be considered in
patients with AR and asthma.
Limitations of the current study include a reli-
ance on prescription data as a surrogate for actual
medication use. This may have resulted in an over-
estimation of MP-AzeFlu use, and an under-
estimation of its effect on asthma outcomes.
OPCRD does not capture information on rhinitis
classification, severity, phenotype, or sensitization
patterns which may have provided further insight
into the impact of MP-AzeFlu on asthma outcomes,
particularly asthma exacerbations. Additional sub-
analyses stratified by gender, age, baseline
asthma severity and presence of nasal polyps
would also have been interesting but insufficient
sample size precluded meaningful assessment.
OPCRD also does not capture over-the-counter
(OTC) medication use. Although all potential MP-
AzeFlu use is captured (as MP-AzeFlu is only
available on prescription in the United Kingdom), it
is possible that patients used other OTC AR
medications too. Finally, while we attempted to
address confounding factors such as ICS use (the
findings were similar to those of the main analysis),
recent and ever INS use, and asthma exacerbation
history, it is possible (as with all observational
studies) that unrecognized confounding factors
affected asthma outcomes. To counterbalance
these limitations, it should be noted that, by virtue
of its size, the OPRCD enabled us to study a large
cohort of patients with AR and asthma (>1000patients), treated with MP-AzeFlu in primary care in
the United Kingdom. The pre-post study design
allowed patients to act as their own control. Data
captured into the OPCRD comes from electronic
medical records and has been used frequently for
observational research.13,14,55 These data provide
a snapshot of how these patients are managed in
real-life in practices all over the United Kingdom,
and enabled us to answer important research
questions, for which an RCT is unsuitable or un-
feasible (due to cost and sample size re-
quirements, for example). Although RCTs are
currently considered as the gold-standard study
design to determine a cause and effect relation-
ship, they are primarily designed to answer regu-
latory questions, include a highly selected and
homogenous patient population and so seldom
represent the wider spectrum of patients seen in
clinical practice. The OPCRD data presented in the
current study are more heterogeneous in nature
(than RCTs), are obtained without RCT supports
(eg, free medication, compliance checks, etc) and
restrictions (eg, strict inclusion/exclusion criteria)
and so are more generalizable to patients seeking
medical care in real life.30 Finally, by virtue of the
number of disease-specific variables collected by
OPRCD, we were able to assess the impact of MP-
AzeFlu on a comprehensive list of asthma-related
outcomes.
In conclusion, our study shows the beneficial
effect of MP-AzeFlu (prescribed for the treatment
of AR) on asthma outcomes in patients with both
AR and asthma in primary care in the United
Kingdom. These results are noteworthy since they
were obtained in patients seen in real-life clinical
practice, and in asthma that was (apparently) well-
treated, but remained uncontrolled. Our findings
endorse Allergic Rhinitis and its Impact on Asthma
(ARIA) and primary care guideline recommenda-
tions to treat both the upper and lower airways
together,8,15 and serve as a call to action to always
check for rhinitis in asthmatic patients. In patients
with AR and asthma, getting the upper airway
under control may be just as important as
controlling other factors which impact asthma
control (eg, adherence, inhaler technique). These
results should be validated by directly comparing
the impact of MP-AzeFlu and INS alone on
asthma outcomes in patients with AR and asthma
in randomized controlled trials, real-world
Volume 13, No. 12, Month 2020 15databases and pragmatic trials, and to quantify the
socioeconomic benefit of MP-AzeFlu-associated
asthma benefits both directly (eg, reduced
healthcare resource utilization) and indirectly (eg,
absenteeism/presenteeism).
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